In FY16-17, operating income was up by eight per cent to Rs 15,090 crore
Aurobindo Pharma has recently posted its Q4 FY16-17 and FY16-17 financial results. In FY16-17, operating income was up by eight per cent to Rs 15,090 crore vs Rs 13,955 crore. EBIDTA before forex and other income was up eight per cent to Rs 3,434 crore vs Rs 3,188 crore; EBITDA margin was at 22.8 per cent. PAT after JV share, minority interest and OCI was up by 13 per cent to Rs 2,296 crore vs Rs 2,024 crore. Basic and diluted EPS was 39.33 per share respectively. R&D spend was at Rs 543 crore, 3.6 per cent of the revenue. Formulations business registered a growth nine per cent at Rs 12,045 crore (80per cent of revenue). API business registered five per cent growth at Rs 3,042 crore (20 per cent of sales). The board has considered and approved an interim dividend @ 125 per cent i.e., Rs 1.25 per equity share of Rs 1.
In Q4 FY16-17 on YoY basis, the operating income was at Rs 3,642 crore vs Rs 3,746 crore. EBIDTA before forex and other income was at Rs 721 crore vs Rs 866 crore and EBITDA margin was at 19.8per cent. PAT after JV share, minority interest and OCI was at Rs 532.9 crore as against Rs 554.4 crore in the corresponding previous period.
N Govindarajan, MD, Aurobindo Pharma said, “We have registered 8 per cent Y-o-Y revenue growth in FY17 despite a challenging environment in select markets. We continue to invest in building a differentiated and speciality product portfolio, which will sustain the growth momentum for the future.”